The FDA Heard Us Loud and Clear

Sep 18, 2017

On September 11, 2017, the Food and Drug Administration (FDA) held a half-day patient-focused drug development (PFDD) meeting focused exclusively on alopecia areata. The goal was to collect patient perspectives on current and potential treatment options and learn about the ways alopecia areata impacts our everyday lives. A resounding theme was the need for effective therapeutic options for all age groups with the disease.

Novel Findings on the Role of T cells in Alopecia Areata
Study in RA Shows No Rise in Lymphoma Risk with Tofacitinib